Sanofi, Schaeffler Share Price is in Focus as Boards Consider Dividend Today

Sanofi India and Schaeffler India share price will be in focus today, February 27, 2025, as both companies are set to announce their dividend decisions.

Sanofi India Board Meeting

Sanofi India’s Board of Directors is scheduled to meet today to:

• Approve the audited financial statements (Standalone & Consolidated) for Q4 and FY 2024 (ended December 31, 2024).
• Consider and recommend a final dividend for FY 2024.

Sanofi had previously notified the exchanges on February 13, 2025, about its plan to propose a dividend.

Schaeffler India Board Meeting

Schaeffler India’s Board of Directors will meet today to:

• Approve the audited financial results (Standalone & Consolidated) for Q4 and FY 2024 (ended December 31, 2024).
• Consider recommending a dividend for 2024 if deemed appropriate.

The company also confirmed that its trading window has been closed since January 1, 2025, and will remain closed until March 1, 2025, in compliance with its Insider Trading Policy.

Other Key Developments

Sanofi India’s RTA Name Change

Sanofi India informed the exchanges in January 2025 that its Registrar and Transfer Agent (RTA) has changed its name from Link Intime India Private Limited to MUFG Intime India Private Limited. This follows the acquisition of Link Group by Mitsubishi UFJ Trust & Banking Corporation.

Shantai Industries to Consider Stock Split

The Board of Directors of Shantai Industries Ltd will meet today at 1:00 PM at the company’s registered office in Surat, Gujarat to discuss:

1. Increasing the company’s Authorised Share Capital.
2. Sub-dividing (splitting) the equity shares of the company.

Investors will be watching these announcements closely as they could impact the stock prices of the respective companies.

Conclusion

Investors will closely monitor the dividend announcements from Sanofi and Schaeffler, while Shantai Industries’ stock split decision could impact its future market performance.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.